Core Viewpoint - Filinger's actual controller is planning a share transfer that may lead to a change in control of the company, prompting a temporary suspension of its stock trading to ensure fair information disclosure and protect investor interests [1] Group 1: Company Overview - Filinger primarily engages in the research, design, production, and sales of wooden flooring and customized home furnishings, with key products including laminate flooring, multilayer solid composite flooring, three-layer solid flooring, solid wood flooring, and customized furniture [1] - In 2024, Filinger faced significant external pressures and internal challenges, resulting in a decline in all major business indicators, with operating revenue of 336 million yuan, a year-on-year decrease of 14.86%, and a net profit of -37.31 million yuan [1] Group 2: Business Challenges and Strategies - In the flooring business, Filinger is experiencing increased operational pressure due to insufficient market demand and intensified product price competition, prompting the company to reflect on strategies for short-term profitability and long-term stable growth [2] - The company is actively improving internal controls and self-innovation, focusing on budget control, reducing unnecessary costs, and enhancing efficiency across various business and management aspects [2] - In the home furnishing sector, Filinger is working to expand its partnerships and improve sales channels, with a focus on establishing a high-end brand image and enhancing the professional capabilities of its team [2]

带领安奈儿（002875）在资本市场走过八个年头之后，曹璋、王建青夫妇决定退出。6月2日晚间，安奈儿披露公告称，曹璋和王建青拟通过向交易对手方转 让公司13.03%的股份等方式，使交易对手方获得公司控制权，公司股票自6月3日起停牌。值得一提的是，披露易主消息前一交易日，安奈儿股价涨停收 盘，目前最新总市值36亿元。曹璋、王建青夫妇决定退出背后，安奈儿经营业绩每况愈下，净利已连续5年亏损，并且今年一季度净利仍处于亏损状态，尚 未扭亏。 股价"抢跑" 据了解，安奈儿2017年6月登陆资本市场，公司主营业务为"ANNIL 安奈儿"品牌童装的研发设计、供应链管理、品牌运营及产品销售，也被称为A股"童装第 一股"，实控人为曹璋、王建青夫妇。 截至今年一季度末，曹璋、王建青分别是安奈儿单一第一大、第二大股东，持股比例分别为19.13%、8.25%，两人合计直接持有上市公司27.38%的股份。 决定让出上市公司控制权背后，安奈儿近年来经营业绩并不乐观。 6月2日，安奈儿披露的"筹划公司控制权变更事项停牌公告"显示，本次的交易对手方主要从事投资管理业务，具体转让比例和实施方案尚待进一步沟通确 定。若本次交易完成，公司的控股股 ...

Core Viewpoint - Filinger Home Technology Co., Ltd. is undergoing a potential change in control as its actual controller, Ding Furui, is planning to transfer shares, which may lead to a shift in company governance [1][4]. Group 1: Company Overview - Filinger was listed in 2017 and primarily engages in the production and after-sales service of solid wood and composite flooring, with its main brand being "Filinger" [3]. - The largest shareholder is Filinger Holdings Ltd., a foreign entity, holding 28.04% of the shares, while Ding Furui and his associates collectively hold 44.56% [3]. Group 2: Financial Performance - The company has experienced a continuous decline in performance, transitioning from profit to loss. Revenue figures from 2020 to 2024 are as follows: 602 million, 782 million, 523 million, 395 million, and 336 million yuan, with net profits of 60.88 million, 20.33 million, 9.72 million, -24.18 million, and -37.31 million yuan respectively [4]. - The decline in performance is attributed to reduced home decoration demand due to the real estate market adjustment, intensified product price competition, insufficient orders, and high overall production costs [4]. Group 3: Shareholder Dynamics - The decline in performance has led to escalating conflicts between foreign shareholders and Ding Furui, with the German chairman frequently abstaining from board votes. There have also been multiple resignations among the company's directors and executives [5]. - Filinger Holdings Ltd. plans to reduce its stake by up to 10.66 million shares, representing 3% of the total share capital, while other executives also plan to sell portions of their shares [5]. Group 4: Regulatory Issues - Ding Furui and the company faced regulatory scrutiny from the China Securities Regulatory Commission for failing to disclose related party transactions properly, which involved significant contracts with associated companies [6][7]. - The contracts in question had values of 91.78 million yuan and 200 million yuan, constituting 9.97% and 21.73% of the company's latest audited net assets, respectively [6][7].

Core Viewpoint - Filinger Home Technology Co., Ltd. is undergoing a potential change in control as its actual controller, Ding Furu, is planning to transfer shares, which may lead to a shift in company governance [1][10]. Group 1: Company Overview - Filinger was listed in 2017 and primarily engages in the production and after-sales service of solid wood and composite flooring, with its main brand being "Filinger" [3]. - The largest shareholder is Filinger Holdings Limited, holding 28.04% of shares, while Ding Furu and his associates collectively own 44.56% [3]. Group 2: Financial Performance - The company's financial performance has been declining, with revenues from 2020 to 2024 recorded as 602 million, 782 million, 523 million, 395 million, and 336 million yuan, respectively. Net profits during the same period were 60.88 million, 20.33 million, 9.72 million, -24.18 million, and -37.31 million yuan [4]. - The decline in performance is attributed to reduced demand in the home decoration market due to real estate adjustments, increased competition, and high fixed costs that could not be diluted [4]. Group 3: Shareholder Actions - In early May, Filinger announced that its largest shareholder plans to reduce holdings by up to 10.66 million shares, accounting for 3% of the total share capital [5]. - Other executives, including the general manager and vice presidents, also plan to reduce their shareholdings during the specified period [6]. Group 4: Regulatory Issues - Ding Furu and the company faced regulatory scrutiny from the China Securities Regulatory Commission for failing to disclose related party transactions properly, which involved significant contract amounts relative to the company's net assets [8][9].

证券代码：002826 证券简称：易明医药 公告编号：2025-033 西藏易明西雅医药科技股份有限公司 关于筹划公司控制权变更进展暨延期复牌的公告 和巨潮资讯网（www.cninfo.com.cn）上披露的《关于筹划公司控制权变更事项 的停牌公告》。 二、进展情况 截至本公告披露日，公司控股股东、实际控制人与相关各方正在积极推动本 次重大事项的各项工作，协议尚未正式签署，公司预计无法在 2025 年 5 月 29 日 （星期四）开市起复牌，根据《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第 6 号——停复牌》等有关规定，经公司向深圳证券交 易所申请，公司股票（证券简称：易明医药，证券代码：002826）自 2025 年 5 月 29 日（星期四）开市起继续停牌，预计停牌时间不超过 3 个交易日。 停牌期间，公司将根据相关事项进展情况，严格按照法律法规的有关规定及 时履行信息披露义务。公司指定的信息披露媒体为《证券时报》《上海证券报》 及巨潮资讯网（http://www.cninfo.com.cn），待上述事项确定后，公司将及时 发布相关公告并申请复牌。因该事项存在不确定性，敬请投资者 ...

Core Viewpoint - The company is undergoing a potential change in control as the major shareholder and actual controller, Gao Fan, is planning to transfer control, which has led to a temporary suspension of trading in its shares due to significant uncertainty surrounding the matter [1][2]. Group 1: Shareholder Changes - Gao Fan, the founder of the company, holds 48.80 million shares, accounting for 25.59% of the total share capital, making him the largest shareholder [4]. - Speculation about Gao Fan's exit from the company has been ongoing for several years, especially after he stepped down from key management positions in September 2021 [5]. - Following his resignation, Gao Fan initiated a share reduction plan in June 2022, intending to sell up to 9.56 million shares, which represents 5% of the total share capital [6]. Group 2: Share Reduction History - By the end of the reduction plan in December 2022, Gao Fan had sold 635,800 shares, which is 0.33% of the total share capital [7]. - In February 2023, he announced another reduction plan, aiming to sell up to 5% of the total share capital, but later decided to terminate this plan early in June 2023, having sold 1.5353 million shares, or 0.81% of the total share capital [8]. Group 3: Company Performance - The company has shown lackluster performance since its listing in 2016, with revenues of 602.62 million, 725.46 million, 856.73 million, 667.04 million, and 651.88 million from 2020 to 2024, respectively [12]. - Net profits during the same period were 41.09 million, 43.47 million, 46.12 million, 15.73 million, and 47.46 million, indicating a significant drop in 2023 [12]. - In 2023, the company experienced a 22.14% decline in revenue and a drastic 65.9% drop in net profit, attributed to market conditions and underperformance of acquired subsidiaries [15]. Group 4: Acquisition and Impairment - The company acquired a controlling stake in Inner Mongolia Bostai Enterprise Management Service Co., Ltd. for 30.6 million, but the performance did not meet expectations, leading to a goodwill impairment of approximately 20 million [14].

每经记者｜赵李南 每经编辑｜文多 据罗平锌电公告，锌电公司拟向受让方曲靖市发展投资集团有限公司（以下简称曲靖发投）协议转让其 所持有约7243万股上市公司无限售流通股股份，占罗平锌电总股本的22.3960%。 截至今年一季度末，锌电公司持有罗平锌电27.40%的股份。 工商资料显示，曲靖发投的唯一股东为曲靖市国资委。据曲靖发投官网，该公司属曲靖市人民政府授权 曲靖市国资委履行出资人职责的市属国有独资企业，注册资本18.55亿元，下设城市运营投资、水务投 资、产业和金融投资、国有资产运营管理4个功能板块。 罗平锌电表示，本次权益变动的相关事项将根据《上市公司国有股权监督管理办法》的要求，取得有权 国资监管部门的批准或许可后方可进行。 罗平锌电称，由于上述事项尚在筹划中，且尚未签署正式协议，具有重大不确定性。为保证公平信息披 露，避免公司股价异常波动，维护广大投资者利益，经公司向深圳证券交易所申请，公司股票自2025年 5月28日开市起停牌，预计停牌时间不超过2个交易日。 "该事项目前处于筹划阶段，尚存在重大不确定性，敬请广大投资者注意投资风险。"罗平锌电称。 内部控制或得到改善 5月27日，罗平锌电（SZ002 ...

Core Viewpoint - *ST Dongjing is undergoing a potential change in control, with a new investor from the equity investment industry planning to acquire a significant stake, leading to a trading suspension for up to two days starting May 28 [2][6]. Group 1: Control Change Announcement - On May 27, *ST Dongjing announced that its control might change due to negotiations with a third-party investor, which could acquire 25% to 29.99% of the voting rights [6][9]. - The current largest shareholders, Ningbo Meishan Free Trade Port Area Blue Ocean Investment Management Center and shareholder Li Qingyue, hold 10.02% and 6.85% of shares, respectively [6][9]. - The company has no controlling shareholder or actual controller as of the 2024 annual report [6][9]. Group 2: Stock Performance - Following the announcement, *ST Dongjing's stock hit the daily limit up, closing at 6.26 yuan per share, with a total market capitalization of 1.524 billion yuan [2][9]. - The stock's trading volume was reported at 131,600 shares, indicating significant investor interest [4]. Group 3: Financial Performance - For the fiscal year 2024, *ST Dongjing reported an audited revenue of 217 million yuan, with a net loss attributable to shareholders of 73.45 million yuan [11]. - The company has been placed under delisting risk warning since March 26 due to financial performance issues, with a daily price fluctuation limit of 5% [11]. Group 4: Management's Future Plans - The management has denied any plans for equity transfer during a recent earnings call, emphasizing a focus on the core crystal oscillator business and efforts to improve operational efficiency and cost control [9][11]. - The company aims to enhance sales resources and R&D investments to maintain growth and seek new business opportunities [11].

证券代码：603100 证券简称：川仪股份 公告编号：2025-033 重庆川仪自动化股份有限公司 （一）股份受让方和表决权受托方基本情况 | 名称 | 国机仪器仪表（重庆）有限公司 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 统一社会信用代码 | 91500000MAEAUQPT2T | | | | | | | | 法定代表人 | 周开荃 | | | | | | | | 注册资本 | 20,000 万元人民币 | | | | | | | | 注册地址 | 重庆市两江新区星光大道 62 | 号 C | 区 | 2 | 楼 | 16-1 | 号 | 关于控股股东签署《股份转让框架协议的补充协议》《表决权委托协议》 暨控制权拟发生变更的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 2025 年 5 月 27 日，川仪股份直接控股股东四联集团与国机集团、国机 仪器仪表公司签署《股份转让框架协议的补充协议》，明确由国 ...

Core Viewpoint - The article discusses the significant changes in the control of Sailong Pharmaceutical Group Co., Ltd. (*ST Sailong, 002898) following the signing of a share transfer agreement, alongside the company's poor financial performance leading to a delisting risk warning. Group 1: Share Transfer and Control Change - The controlling shareholders, Cai Nanguai and Tang Lin, signed a share transfer agreement to sell 14.16% of the company's shares to Hainan Yayi, amounting to a total transaction value of RMB 199,297,640.00 at a price of RMB 8 per share [1] - Following the transaction, Hainan Yayi will become the controlling shareholder, and the company will have no actual controller since Hainan Yayi currently has no actual controller [1] - The shareholding structure will change significantly, with Cai Nanguai's shareholding dropping from 51.15% to 38.36%, and Tang Lin's from 5.47% to 4.10% [1] Group 2: Financial Performance - Sailong Pharmaceutical reported a revenue of RMB 263.57 million in 2024, a decrease of 15.15% compared to 2023, and a net loss of RMB 33.15 million, a decline of 447.67% year-on-year [2][3] - The company has been issued a delisting risk warning due to its negative net profit and revenue falling below RMB 300 million [3][4] Group 3: Regulatory Actions - The company received a warning letter from the Guangdong Securities Regulatory Bureau due to discrepancies between its earnings forecast and actual performance, as well as failure to disclose potential delisting risks in a timely manner [4][5] - Key executives, including the chairman and financial director, were held responsible for the company's non-compliance with disclosure regulations [5] Group 4: New Shareholder Background - Hainan Yayi, the acquiring entity, was established on May 15, 2025, specifically for this transaction and currently has no actual business operations [6] - The partnership structure of Hainan Yayi indicates that it lacks an actual controller, with decision-making requiring unanimous agreement among partners [8]